公开(公告)号：US20200277378A1

公开(公告)日：2020-09-03

申请号：US16764102

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Catherine Anne Sabatos-Peyton ,  Jennifer Marie Mataraza ,  Kenzie MacIsaac ,  Eunice Kwak ,  Jason Faris ,  Glenn Dranoff ,  Marion Wiesmann ,  Fiona Sharp ,  Adam Crystal ,  John Scott Cameron ,  Robert Martin Strieter ,  Lilli Petruzzelli ,  Shamsah Kazani ,  David Andrew Sandham ,  Neil John Press ,  Keith Hoffmaster

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.

公开(公告)号：US20240245670A1

公开(公告)日：2024-07-25

申请号：US17415923

申请日：2019-12-19

Applicant: Novartis AG

Inventor： Simone BONAZZI ,  Adam Crystal ,  John Scott Cameron ,  Eva Marie Genevieve D'Hennezel ,  Glenn Dranoff ,  Ry Roger Forseth ,  Dominik Johannes Hainzl ,  Jacqueline Kinyamu-Akunda ,  Guiqing Liang ,  Lilly Mary Petruzzelli

IPC: A61K31/4545 ,  A61K9/00 ,  A61K31/55 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61K9/0053 ,  A61K31/55 ,  A61P35/00

Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.